Fig. 2

Characterization of iMPCs during monolayer differentiation. a–e Representative immunostaining of Pax3 (a), Myf5 (b), MyoD (c), and MyoG (d), and corresponding quantification (e) during iMPC expansion. Scale bar=100 µm. f Representative FACS analysis for CD56 in H9 and TRiPSC derived iMPCs. g Representative immunostaining (top) and quantification (bottom) of Pax7⁺ and MyoG⁺ cell populations for H9 and TRiPS derived myotubes at 2 weeks of monolayer differentiation. (n = 6 samples from 2 differentiations for each cell line). h Representative immunostaining and quantification of GFP⁺/Pax7⁺ and GFP^-/Pax7⁺ cell pools at 2 weeks of monolayer differentiation. Scale bar=50 µm. (n = 4 samples from 2 differentiations for each cell line). i Representative immunostaining and quantification of myotube diameter at 1, 2, and 4 weeks of monolayer differentiation. (*P < 0.05 vs. 1 week, ^#P < 0.05 vs. 4 week, Tukey–Kramer HSD test; n = 6 samples from 2 differentiations for each cell line). Scale bars=50 µm. Data are presented as mean ± SEM